Home > Education Hub > We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

News

Category:

M&A Pharma

Published on:

December 20, 2020

Alira Health is pleased to announce its role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Merieux Equity Partners is a global asset manager specialized in the healthcare and nutrition sectors. Cell-Easy is a novel French pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies for preclinical and clinical studies. This fund raising aims at accelerating the company’s growth in France and internationally, by expanding the Cell-Easy Management Team and strengthening the company’s commercial presence in key regions.

To read the press release on BusinessWire, click here.

For more information, contact Joris Pezzini.

For more information about Alira Health Transaction Advisory services

Click here

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

For more information about Alira Health Transaction Advisory services

Related news

What You Should Know Before Choosing a Healthcare Transaction Advisory Firm

Infographic: 2021 Trends in Healthcare

2020 Year in Review

Welcome Daniela Sica, Vice President, Business Development, Pharma and Biotech

We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel

WHO Guideline: Summary of Recommendations on Pharmaceutical Pricing Policies

Our Parallel Trade Expertise

Our locations around the globe